FDA
-
-
-
-
-
-
-
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
-
-
-
-
-
-
-
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
-
-
-
-
-
-
-
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
-
-
-
-
-
-
-
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs
-
-
-
-
-
-
-
PharmaTher Announces Publication of Research Data for KETABET™
-
-
-
-
-
-
-
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
-
-
-
-
-
-
-
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

